SCHEMBL3325622

SCHEMBL3325622

NC(=S)NC1CCN(Cc2ccccc2)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.68
▸ KMT2A Q03164 5/20 0.68
▸ MAPK1 P28482 2/20 0.68
▸ KCNH2 Q12809 1/20 0.68
▸ SIGMAR1 Q99720 2/20 0.65
▸ LMNA P02545 3/20 0.62
▸ POLB P06746 2/20 0.62
▸ MAPT P10636 1/20 0.62
▸ MEN1 O00255 2/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61
▸ DRD4 P21917 2/20 0.60
▸ DRD2 P14416 1/20 0.60
▸ DRD3 P35462 1/20 0.60
▸ GAA P10253 2/20 0.60
▸ ALOX12 P18054 1/20 0.60
▸ HTT P42858 1/20 0.60
▸ DPP7 Q9UHL4 1/20 0.59
▸ BCHE P06276 1/20 0.59
▸ ACHE P22303 1/20 0.59
▸ BACE1 P56817 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL8824061 0.98 ALDH1A1 (0.67) ALDH1A1KMT2AMAPK1KCNH2SIGMAR1
SCHEMBL5844682 0.91 BACE1 (0.61) ALDH1A1KMT2AMAPK1KCNH2SIGMAR1
SCHEMBL19743237 0.87 KCNH2 (0.60) ALDH1A1KMT2AMAPK1KCNH2SIGMAR1
SCHEMBL14100444 0.87 SIGMAR1 (0.60) ALDH1A1KMT2AMAPK1KCNH2SIGMAR1
SCHEMBL27780880 0.85 SIGMAR1 (0.67) ALDH1A1KMT2AMAPK1KCNH2SIGMAR1
SCHEMBL5230894 0.85 SIGMAR1 (0.74) KMT2AMAPK1KCNH2SIGMAR1POLB
SCHEMBL4202978 0.85 SIGMAR1 (0.65) ALDH1A1KMT2AMAPK1KCNH2SIGMAR1
SCHEMBL2425554 0.81 SIGMAR1 (0.78) KMT2AMAPK1SIGMAR1POLBDRD4
Hydrochloric Acid SCHEMBL21410212 0.80 SIGMAR1 (0.76) KMT2AMAPK1SIGMAR1POLBDRD4
SCHEMBL5501378 0.80 KMT2A (0.57) ALDH1A1KMT2AMAPK1KCNH2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353089-B2 Compositions and methods for the treatment of malaria SAINT LOUIS UNIVERSITY (US) 2016-05-31 — — US disclosed
WO-2015028989-A1 NOVEL HETEROCYCLIC COMPOUNDS AS ANTIMALARIAL AGENTS ACTELION PHARMACEUTICALS LTD (CH) 2015-03-05 — — WO disclosed
US-8933101-B2 Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2015-01-13 — — US disclosed
WO-2014160775-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA SAINT LOUIS UNIVERSITY (US) 2014-10-02 — — WO disclosed
US-20140296532-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2014-10-02 — — US disclosed
US-20100120860-A1 THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS JANSSEN-CILAG S.A., (ES) 2010-05-13 — — US disclosed
EP-2148879-A1 THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2010-02-03 — — EP disclosed
WO-2008128996-A1 THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-10-30 — — WO disclosed
EP-0719775-B1 Substituted 4-phenyl thiazole derivatives, process for their preparation and pharmaceutical compositions containing them SANOFI SYNTHELABO (FR) 2000-07-12 — — EP disclosed
WO-2000024740-A1 METHOD FOR PREPARING 4-(2-AMINO-1,3-THIAZOL-4-YL) BENZENECARBOXIMIDAMIDE DERIVATIVES SANOFI-SYNTHELABO (FR) 2000-05-04 — — WO disclosed
EP-0981518-A1 SUBSTITUTED HETEROCYCLIC NITROGENS, METHODS FOR PRODUCING SAME AND THEIR USE AS PEST CONTROL AGENT Hoechst Schering AgrEvo GmbH (DE) 2000-03-01 — — EP disclosed
WO-1998051674-A1 SUBSTITUTED HETEROCYCLIC NITROGENS, METHODS FOR PRODUCING SAME AND THEIR USE AS PEST CONTROL AGENT HOECHST SCHERING AGREVO GMBH (DE) 1998-11-19 — — WO disclosed
EP-0719775-A1 Substituted 4-phenyl thiazole derivatives, process for their preparation and pharmaceutical compositions containing them SANOFI (FR) 1996-07-03 — — EP disclosed
EP-0206415-B1 (4-PIPERIDINYLMETHYL AND -HETERO)PURINES JANSSEN PHARMACEUTICA N.V. (BE) 1993-01-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296532-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA BACE2, DNPEP, ACE ALDH1A1 1822/4885KMT2A 960/4885MAPK1 4778/4885
US-20100120860-A1 THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS GRIN2A, DRD2, GRIN2C ALDH1A1 735/4885KMT2A 971/4885MAPK1 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback